Boan Biotech’s Boluojia® Wins NMPA Approval

Shandong Boan Biotechnology Company., Limited. Class H (HK:6955) has released an update.

Shandong Boan Biotechnology Co., Ltd. has announced the NMPA approval of its denosumab injection, Boluojia®, for treating unresectable giant cell tumor of bone in China. The product, a biosimilar to XGEVA®, has shown high similarity in comprehensive comparative studies and is set to expand globally, with international clinical trials underway and plans to submit applications to the EMA, FDA, and Japan’s PMDA. The company anticipates strong market potential for Boluojia® based on significant clinical demand and value.

For further insights into HK:6955 stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.